Speciality Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Education Dialogues
    • Business Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Speciality Medical Dialogues
    • Editorial
    • News
        • Anesthesiology
        • Cancer
        • Cardiac Sciences
        • Critical Care
        • Dentistry
        • Dermatology
        • Diabetes and Endo
        • Diagnostics
        • ENT
        • Featured Research
        • Gastroenterology
        • Geriatrics
        • Medicine
        • Nephrology
        • Neurosciences
        • Nursing
        • Obs and Gynae
        • Ophthalmology
        • Orthopaedics
        • Paediatrics
        • Parmedics
        • Pharmacy
        • Psychiatry
        • Pulmonology
        • Radiology
        • Surgery
        • Urology
    • Practice Guidelines
        • Anesthesiology Guidelines
        • Cancer Guidelines
        • Cardiac Sciences Guidelines
        • Critical Care Guidelines
        • Dentistry Guidelines
        • Dermatology Guidelines
        • Diabetes and Endo Guidelines
        • Diagnostics Guidelines
        • ENT Guidelines
        • Featured Practice Guidelines
        • Gastroenterology Guidelines
        • Geriatrics Guidelines
        • Medicine Guidelines
        • Nephrology Guidelines
        • Neurosciences Guidelines
        • Obs and Gynae Guidelines
        • Ophthalmology Guidelines
        • Orthopaedics Guidelines
        • Paediatrics Guidelines
        • Psychiatry Guidelines
        • Pulmonology Guidelines
        • Radiology Guidelines
        • Surgery Guidelines
        • Urology Guidelines
    LoginRegister
    Speciality Medical Dialogues
    LoginRegister
    • Home
    • Editorial
    • News
      • Anesthesiology
      • Cancer
      • Cardiac Sciences
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endo
      • Diagnostics
      • ENT
      • Featured Research
      • Gastroenterology
      • Geriatrics
      • Medicine
      • Nephrology
      • Neurosciences
      • Nursing
      • Obs and Gynae
      • Ophthalmology
      • Orthopaedics
      • Paediatrics
      • Parmedics
      • Pharmacy
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
    • Practice Guidelines
      • Anesthesiology Guidelines
      • Cancer Guidelines
      • Cardiac Sciences Guidelines
      • Critical Care Guidelines
      • Dentistry Guidelines
      • Dermatology Guidelines
      • Diabetes and Endo Guidelines
      • Diagnostics Guidelines
      • ENT Guidelines
      • Featured Practice Guidelines
      • Gastroenterology Guidelines
      • Geriatrics Guidelines
      • Medicine Guidelines
      • Nephrology Guidelines
      • Neurosciences Guidelines
      • Obs and Gynae Guidelines
      • Ophthalmology Guidelines
      • Orthopaedics Guidelines
      • Paediatrics Guidelines
      • Psychiatry Guidelines
      • Pulmonology Guidelines
      • Radiology Guidelines
      • Surgery Guidelines
      • Urology Guidelines
    • Home
    • Practice Guidelines
    • Cardiac Sciences Guidelines
    • AHA , ACC Guideline...

    AHA , ACC Guideline for Management of ventricular arrhythmias

    Written by Medha Baranwal Baranwal Published On 2018-07-07T19:01:01+05:30  |  Updated On 7 July 2018 7:01 PM IST
    AHA , ACC Guideline for Management of ventricular arrhythmias

    The American Heart Association (AHA), American College of Cardiology (ACC) and Heart Rhythm Society (HRS) have developed a guideline for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death (SCD).


    The guideline is published in the journal JAMA Cardiology.

    This synopsis focuses on recommendations on managing Ventricular Arrhythmias, VA and Sudden Cardiac Death, SCD risk that is associated with cardiac channelopathies. All implantable cardioverter-defibrillator (ICD) recommendations require that patients have meaningful survival of greater than 1 year.


    Key Recommendations:

    • In first-degree relatives of patients who have a causative mutation for long QT syndrome, catecholaminergic polymorphic ventricular tachycardia, short QT syndrome, or Brugada syndrome, genetic counseling and mutation-specific genetic testing are recommended.




    • In patients with a cardiac channelopathy and sudden cardiac arrest, an ICD is recommended.




    • In patients with long QT syndrome with a resting corrected QT interval greater than 470 milliseconds, a β-blocker is recommended.




    • In high-risk patients with symptomatic long QT syndrome in whom a β-blocker is ineffective or not tolerated, an intensification of therapy with additional medications (guided by considering the particular long QT syndrome type), left cardiac sympathetic denervation, and/or an ICD is recommended.




    • In patients with long QT syndrome and recurrent appropriate ICD shocks despite receiving the maximum tolerated doses of a β-blocker, an intensification of medical therapy with additional medications (guided by considering the particular long QT syndrome type) or left cardiac sympathetic denervation is recommended.




    • In patients with clinically diagnosed long QT syndrome, genetic counseling and genetic testing are recommended.




    • In patients with suspected long QT syndrome, ambulatory electrocardiographic monitoring, recording the electrocardiogram (ECG) lying down and immediately on standing, and/or treadmill exercise testing can be useful for establishing a diagnosis and monitoring the response to therapy.




    • In asymptomatic patients with long QT syndrome and a resting corrected QT interval of less than 470 milliseconds, long-term therapy with a β- blocker is reasonable.




    • In patients with catecholaminergic polymorphic ventricular tachycardia, a β-blocker is recommended.




    • In patients with catecholaminergic polymorphic ventricular tachycardia and recurrent sustained VT or syncope, while the patient is receiving adequate or maximally tolerated β-blocker, treatment intensification with either combination medication therapy (eg, beta blocker, flecainide), left cardiac sympathetic denervation, and/or an ICD is recommended.




    • In patients with catecholaminergic polymorphic ventricular tachycardia and clinical ventricular tachycardia (VT) or exertional syncope, genetic counseling and genetic testing are reasonable.




    • In asymptomatic patients with only an inducible type 1 Brugada electrocardiographic pattern, observation without therapy is recommended.




    • In patients with Brugada syndrome with a spontaneous type 1 Brugada electrocardiographic pattern and cardiac arrest sustained VA, or a recent history of syncope presumed to be caused by VA, an ICD is recommended.




    • In patients with Brugada syndrome who are experiencing recurrent ICD shocks for polymorphic VT, an intensification of therapy with quinidine or catheter ablation is recommended.




    • In patients with spontaneous type 1 Brugada electrocardiographic pattern and symptomatic VA who either are not candidates for or decline to have an ICD implanted, quinidine or catheter ablation is recommended.




    • In patients with suspected Brugada syndrome in the absence of a spontaneous type 1 Brugada electrocardiographic pattern, a pharmacological challenge using a sodium channel blocker can be useful for diagnosis.




    • In asymptomatic patients with an early repolarization pattern on ECG, observation without treatment is recommended.




    • In patients with early repolarization pattern on ECG results and cardiac arrest or sustained VA, an ICD is recommended.




    For further information click on the link: 10.1001/jamacardio.2018.1116

    Brugada syndromecardiac arrestcardiac channelopathiescardiac deathchannelopathieschannelopathyimplantable cardioverter defibrillatorJAMA CardiologyQT syndromesuddenVentricular Arrhythmiasβ-blocker
    Source : With inputs from JAMA Cardiology

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medha Baranwal Baranwal
    Medha Baranwal Baranwal
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 12 Oct 2022 7:06 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok